ArticleOral oncology2016
Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.
Article in Oral oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer.Oral oncology · 2018Pooled it
- Spatially defined microenvironmental niches are associated with clinical outcome and tumor ecosystem diversity in head and neck cancer.Med (New York, N.Y.) · 2026Article
- Clinical Impact of Rapid Recurrence in Oral Tongue Squamous Cell Carcinoma and a Nomogram for Early Identification of High-Risk Patients.Clinical and experimental otorhinolaryngology · 2026Article
- Oncogenic viruses and their role in oral cavity and oropharyngeal squamous cell carcinoma: a systematic review.Frontiers in oncology · 2026Review
- Overall and disease-free survival in patients with HPV-positive and HPV-negative oropharyngeal cancer.Einstein (Sao Paulo, Brazil) · 2025Article
- Temporal and spatial patterns of recurrence in oral squamous cell carcinoma, a single-center retrospective cohort study in China.BMC oral health · 2023Article
- Article
- Time to Recurrence Associated With Poor Prognosis in Japanese Oral Squamous Cell Carcinoma Patients.Journal of maxillofacial and oral surgery · 2022Article
- Current perspectives on recurrent HPV-mediated oropharyngeal cancer.Frontiers in oncology · 2022Article
- Patient Burden with Current Surveillance Paradigm and Factors Associated with Interest in Altered Surveillance for Early Stage HPV-Related Oropharyngeal Cancer.The oncologist · 2021Article
- Characterizing distant metastases and survival in oropharyngeal squamous cell carcinoma.Head & neck · 2021Article
- Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status.Cancers · 2021Article
- Fluorodeoxyglucose positron emission tomography/computed tomography identifying pericardial metastasis from early-stage p16-positive oropharyngeal cancer.Clinical case reports · 2020Article
- Prognostic factors for human papillomavirus-positive and negative oropharyngeal carcinomas.The Laryngoscope · 2018Article
- Outcomes utilizing intensity-modulated radiotherapy in oropharyngeal cancers: Tonsils versus base of tongue.Head & neck · 2018Article
- Article
- Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer usingBMC cancer · 2017Article
- Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma.Laryngoscope investigative otolaryngology · 2017Review
- Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.Gynecologic oncology research and practice · 2017Review
- Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesHuman papillomavirus (HPV)-positive tumor status is associated with improved prognosis after disease recurrence in oropharyngeal squamous cell carcinoma (OPSCC). In this study the potential role of survival bias in the relationship between HPV tumor status and the timing of recurrence was evaluated, given conflicting evidence in the literature. MATERIALS &
methodsA secondary analysis was performed on a previously published retrospective two institution study of recurrent OPSCC with known HPV tumor status. Patients were categorized as "early" (surviving <24 months) or "late" survivors (⩾24 months). Timing of first recurrence and overall survival were analyzed using Kaplan-Meier and cox proportional hazard methods. Two-sided p-values <0.05 were considered significant.
resultsIn total 101 patients met criteria including 81 late and 20 early survivors. HPV-positive tumor status was associated with longer time to recurrence in late survivors (median 21.8 vs. 13.8 months, p=0.028). Late survivors had later recurrences in HPV-positive (p<0.001) and HPV-negative patients (p=0.0096), as well as in both locoregional (p<0.0001) and distant metastatic recurrence (p<0.0001). In multivariate analysis, both HPV-positive tumor status (adjusted HR [aHR] 0.48, p=0.006) and survival beyond 24 months (aHR 0.21, p<0.001) were associated with later recurrence. When stratified, HPV tumor status was only associated with later recurrence in late survivors (aHR 0.47, p=0.015).
conclusionsLate survivorship was associated with late recurrence for both HPV-positive and HPV-negative patients. Stratification by survival illustrates how survival bias links late survivorship with late recurrences and contributes to our understanding of the impact of HPV tumor status on the timing of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.